Top in endocrinology: Personalized vs. low-fat diet; real-world data on semaglutide

A personalized diet that targets postprandial glycemic response led to similar weight loss levels compared with a low-fat diet among adults with obesity and abnormal glucose metabolism, a recent study showed.

At 6 months, participants assigned to the low-fat diet lost a mean of 4.31% of their baseline body weight compared with a mean weight loss of 3.26% among those assigned to a personalized diet. These weight changes were not statistically significantly different, according to researchers. It was the top story in endocrinology last week.

Another top story was about the real-world effects of weekly Wegovy (semaglutide, Novo Nordisk) therapy among adults with overweight or obesity.

Read these and more top stories in endocrinology below:

Personalized diet yields similar weight loss as low-fat diet at 6 months

Compared with a low-fat diet, a personalized diet targeting postprandial glycemic response did not lead to greater weight loss at 6 months among adults with abnormal glucose metabolism and obesity, according to study data. Read more.

Real-world data show weekly semaglutide effective for weight loss at 3, 6 months

In real-world data from adults with overweight or obesity, weekly semaglutide therapy of 1.7 mg or 2.4 mg was effective at 3 and 6 months for weight loss amounts similar to those observed in clinical trials, according to researchers. Read more.

DELIVER: Dapagliflozin cuts risk for worsening HF in adults with, without type 2 diabetes

Farxiga (dapagliflozin, AstraZeneca) reduced the risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial. Read more.

Type 2 diabetes remission likely for adults with ‘healthy’ BMI and 10% weight loss

Adults with type 2 diabetes and a BMI of 21 kg/m² to 27 kg/m² have high likelihood of diabetes remission if they lose 10% of their starting weight, researchers reported. Read more.

Hip fracture rates decline during 20-year period

Age-standardized incidence of hip fractures dropped by 27% among women and 20% among men in Norway from 1999 to 2019, with the rising number of hip prostheses accounting for nearly 20% of this decline, according to study data. Read more.